SERENTIL (nda016774)- (EQ 10MG BASE,EQ 25MG BASE,EQ 50MG BASE,EQ 100MG BASE)

Generic Name	MESORIDAZINE BESYLATE	Innovator	NOVARTIS
Dosage	EQ 10MG BASE,EQ 25MG BASE,EQ 50MG BASE,EQ 100MG BASE
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	Expired	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	SERENTIL is indicated for the management of schizophrenic patients who fail to respond to adequately to treatment with other antipsychotic drugs.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 10MG BASE	**	**	-	-	-
EQ 25MG BASE	**	**	-	-	-
EQ 50MG BASE	**	**	-	-	-
EQ 100MG BASE	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of SERENTIL